Patient characteristics
| Factor . | No. (%) . |
|---|---|
| Sex | |
| Female | 28 (32) |
| Male | 59 (68) |
| Disease phase | |
| Chronic | 55 (63) |
| Accelerated | 26 (30) |
| Blastic | 6 (7) |
| HLA type–HLA-A*0201 | |
| Positive | 31 (36) |
| Negative | 56 (64) |
| Source of stem cells for SCT | |
| BM | 24 (28) |
| PBSC | 63 (72) |
| Conditioning regimen | |
| 13.5 Gy TBI, Cy 120 mg/kg, SD CSA | |
| BMT | 24 (28) |
| PBSC transplantation | 15 (17) |
| 13.5 Gy TBI, Cy 120 mg/kg, LD CSA or no CSA; PBSC transplantation | 23 (26) |
| 12 Gy TBI, Cy 120 mg/kg, Flu 125mg/m2, LD CSA or no CSA; PBSC transplantation | 22 (25) |
| Cy 120 mg/kg, Flu 125 mg/m2, CSA ± mycophenolate mofetil; PBSC transplantation | 3 (4) |
| PR1 responses | |
| Patient, n = 28 | 7 (25) |
| Donor, n = 27 | 7 (26) |
| Factor . | No. (%) . |
|---|---|
| Sex | |
| Female | 28 (32) |
| Male | 59 (68) |
| Disease phase | |
| Chronic | 55 (63) |
| Accelerated | 26 (30) |
| Blastic | 6 (7) |
| HLA type–HLA-A*0201 | |
| Positive | 31 (36) |
| Negative | 56 (64) |
| Source of stem cells for SCT | |
| BM | 24 (28) |
| PBSC | 63 (72) |
| Conditioning regimen | |
| 13.5 Gy TBI, Cy 120 mg/kg, SD CSA | |
| BMT | 24 (28) |
| PBSC transplantation | 15 (17) |
| 13.5 Gy TBI, Cy 120 mg/kg, LD CSA or no CSA; PBSC transplantation | 23 (26) |
| 12 Gy TBI, Cy 120 mg/kg, Flu 125mg/m2, LD CSA or no CSA; PBSC transplantation | 22 (25) |
| Cy 120 mg/kg, Flu 125 mg/m2, CSA ± mycophenolate mofetil; PBSC transplantation | 3 (4) |
| PR1 responses | |
| Patient, n = 28 | 7 (25) |
| Donor, n = 27 | 7 (26) |
The median age of patients was 36 years (range, 12–68 years).
SCT indicates allogeneic stem cell transplantation; BM, bone marrow; PBSC, peripheral blood stem cell; TBI, total body irradiation; Cy, cyclophosphamide; SD, standard dose; CSA, cyclosporine; LD, low dose; Flu, fludarabine; and PR1, VLQELNVTV nonapeptide.